

Interstitial Cystitis Association of America, Inc.

Financial Statements
and Independent Auditor's Report

September 30, 2024 and 2023

Interstitial Cystitis Association of America, Inc.

Financial Statements
September 30, 2024 and 2023

Contents

Independent Auditor's Report.....	1-3
<i>Financial Statements</i>	
Statements of Financial Position.....	4
Statements of Activities	5
Statements of Functional Expenses	6-7
Statements of Cash Flows.....	8
Notes to Financial Statements.....	9-13

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Interstitial Cystitis Association of America, Inc.

Opinion

We have audited the accompanying financial statements of Interstitial Cystitis Association of America, Inc. ("ICA"), which comprise the statements of financial position as of September 30, 2024 and 2023; the related statements of activities, functional expenses, and cash flows for the years then ended; and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of ICA as of September 30, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of ICA and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Responsibilities of Management for the Financial Statements (continued)

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about ICA's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements


Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of ICA's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about ICA's ability to continue as a going concern for a reasonable period of time.

Auditor's Responsibilities for the Audit of the Financial Statements (continued)

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Handwritten signature of Rogers & Company PLLC in black ink.

Vienna, Virginia
March 12, 2025

Interstitial Cystitis Association of America, Inc.

Statements of Financial Position
September 30, 2024 and 2023

	2024	2023
Assets		
Cash and cash equivalents	\$ 105,175	\$ 163,920
Accounts receivable	-	11,762
Contributions and grants receivable	26,500	137,860
Prepaid expenses	33,524	1,013
Inventory	354	1,362
Total assets	<u>\$ 165,553</u>	<u>\$ 315,917</u>
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$ 21,288	\$ 25,107
Deferred revenue – corporate partnerships	25,833	25,833
Total liabilities	<u>47,121</u>	<u>50,940</u>
Net Assets		
Without donor restrictions	<u>118,432</u>	<u>264,977</u>
Total net assets	<u>118,432</u>	<u>264,977</u>
Total liabilities and net assets	<u>\$ 165,553</u>	<u>\$ 315,917</u>

See accompanying notes.

Interstitial Cystitis Association of America, Inc.

Statements of Activities
For the Years Ended September 30, 2024 and 2023

	2024	2023
Revenue and Support Without Donor Restrictions		
Contributions	\$ 310,726	\$ 367,416
Grants	80,000	175,000
Corporate partnerships	64,584	43,333
Media campaign	28,300	58,925
Publications	2,695	3,420
Change in value of bank sweep	1,229	23
Total revenue and support without donor restrictions	487,534	648,117
Expenses		
Program services:		
CDC/Boston Children's Hospital sub-grant	47,169	68,748
Research	-	21,067
Advocacy	162,917	146,475
Education	298,117	276,826
Total program services	508,203	513,116
Supporting services:		
General and administrative	35,403	33,413
Fundraising	90,473	102,570
Total supporting services	125,876	135,983
Total expenses	634,079	649,099
Change in Net Assets	(146,545)	(982)
Net Assets, beginning of year	264,977	265,959
Net Assets, end of year	<u>\$ 118,432</u>	<u>\$ 264,977</u>

See accompanying notes.

Interstitial Cystitis Association of America, Inc.

Statement of Functional Expenses
For the Year Ended September 30, 2024

	Program Services				Supporting Services			Total
	CDC/ Boston Children's Hospital Sub-Grant	Advocacy	Education	Total Program Services	General and Administrative	Fundraising	Total Supporting Services	
Advertising	\$ 5,550	\$ -	\$ -	\$ 5,550	\$ -	\$ -	\$ -	\$ 5,550
Government affairs	-	54,061	-	54,061	-	-	-	54,061
Graphic artist	-	-	8,000	8,000	-	-	-	8,000
Storage	-	-	-	-	1,723	-	1,723	1,723
Insurance	-	-	-	-	2,617	-	2,617	2,617
Internet outreach	-	-	16,041	16,041	447	14,087	14,534	30,575
Postage and delivery	-	-	1,489	1,489	2,136	7,211	9,347	10,836
State registration fees and taxes	-	-	-	-	-	10,844	10,844	10,844
Telecommunications	-	-	-	-	1,415	-	1,415	1,415
Printing and reproduction	-	-	8,495	8,495	1	8,293	8,294	16,789
Management fees	13,019	108,492	260,381	381,892	8,679	43,397	52,076	433,968
Office supplies and expenses	-	-	-	-	1,869	-	1,869	1,869
Travel and entertainment	-	364	-	364	1,362	-	1,362	1,726
Contract services	28,600	-	3,479	32,079	-	-	-	32,079
Professional fees	-	-	-	-	13,873	-	13,873	13,873
Bank fees	-	-	-	-	-	6,641	6,641	6,641
Miscellaneous	-	-	-	-	1,281	-	1,281	1,281
Subtotal	47,169	162,917	297,885	507,971	35,403	90,473	125,876	633,847
Costs of goods sold—resource materials	-	-	232	232	-	-	-	232
Total Expenses	\$ 47,169	\$ 162,917	\$ 298,117	\$ 508,203	\$ 35,403	\$ 90,473	\$ 125,876	\$ 634,079

See accompanying notes.

Interstitial Cystitis Association of America, Inc.

Statement of Functional Expenses
For the Year Ended September 30, 2023

	Program Services					Supporting Services			Total
	CDC/ Boston Children's Hospital Sub-Grant	Research	Advocacy	Education	Total Program Services	General and Administrative	Fundraising	Total Supporting Services	
Advertising	\$ 6,445	\$ -	\$ -	\$ -	\$ 6,445	\$ -	\$ -	\$ -	\$ 6,445
Government affairs	-	-	53,736	-	53,736	-	-	-	53,736
Graphic artist	-	-	-	12,000	12,000	-	-	-	12,000
Storage	-	-	-	-	-	2,143	-	2,143	2,143
Insurance	-	-	-	-	-	2,576	-	2,576	2,576
Internet outreach	-	-	-	20,916	20,916	10	19,193	19,203	40,119
Postage and delivery	-	-	-	2,644	2,644	1,151	7,129	8,280	10,924
State registration fees and taxes	-	-	-	-	-	-	10,336	10,336	10,336
Telecommunications	-	-	-	-	-	2,121	-	2,121	2,121
Printing and reproduction	-	-	-	12,496	12,496	329	7,556	7,885	20,381
Management fees	33,706	21,067	92,693	223,305	370,771	8,427	42,133	50,560	421,331
Meeting/conference	-	-	-	-	-	-	6,569	6,569	6,569
Office supplies and expenses	-	-	-	-	-	2,410	-	2,410	2,410
Travel and entertainment	-	-	46	-	46	-	-	-	46
Contract services	28,597	-	-	5,261	33,858	-	-	-	33,858
Professional fees	-	-	-	-	-	13,100	-	13,100	13,100
Bank fees	-	-	-	-	-	-	9,654	9,654	9,654
Miscellaneous	-	-	-	-	-	1,146	-	1,146	1,146
Subtotal	68,748	21,067	146,475	276,622	512,912	33,413	102,570	135,983	648,895
Costs of goods sold—resource materials	-	-	-	204	204	-	-	-	204
Total Expenses	\$ 68,748	\$ 21,067	\$ 146,475	\$ 276,826	\$ 513,116	\$ 33,413	\$ 102,570	\$ 135,983	\$ 649,099

See accompanying notes.

Interstitial Cystitis Association of America, Inc.

Statements of Cash Flows
For the Years Ended September 30, 2024 and 2023

	2024	2023
Cash Flows from Operating Activities		
Change in net assets	\$ (146,545)	\$ (982)
Change in operating assets and liabilities:		
Decrease (increase) in:		
Accounts receivable	11,762	(9,262)
Contributions and grants receivable	111,360	(137,860)
Prepaid expenses	(32,511)	(3)
Inventory	1,008	498
(Decrease) increase in:		
Accounts payable and accrued expenses	(3,819)	(13,696)
Deferred revenue – corporate partnerships	-	25,833
Net cash used in operating activities	(58,745)	(135,472)
Net Decrease in Cash and Cash Equivalents	(58,745)	(135,472)
Cash and Cash Equivalents, beginning of year	163,920	299,392
Cash and Cash Equivalents, end of year	<u>\$ 105,175</u>	<u>\$ 163,920</u>

Interstitial Cystitis Association of America, Inc.

Notes to Financial Statements
September 30, 2024 and 2023

1. Nature of Operations

The Interstitial Cystitis Association of America, Inc. (“ICA”) is a nonprofit health association dedicated to improving the quality of healthcare and lives of people living with interstitial cystitis (IC). ICA provides advocacy, research funding, and education to ensure early diagnosis and optimal care with dignity for people affected by IC.

2. Summary of Significant Accounting Policies

Basis of Accounting and Presentation

ICA’s financial statements are prepared on the accrual basis of accounting. Net assets are reported based on the presence or absence of donor-imposed restrictions, as follows:

- *Net Assets Without Donor Restrictions* – Net assets available for use in general operations and not subject to donor (or certain grantor) restrictions.
- *Net Assets With Donor Restrictions* – Net assets subject to donor- (or certain grantor-) imposed restrictions. ICA reports contributions and grants restricted by donors as increases in net assets without donor restrictions if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor-restricted contributions and grants are reported as increases in net assets with donor restrictions, depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions. There were no net assets with donor restrictions at both September 30, 2024 and 2023.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Cash Equivalents

ICA considers as cash equivalents all highly liquid investments, which can be converted into known amounts of cash and have a maturity period of 90 days or less at the time of purchase.

Interstitial Cystitis Association of America, Inc.

Notes to Financial Statements
September 30, 2024 and 2023

2. Summary of Significant Accounting Policies (continued)

Accounts Receivable

Accounts receivable are due in less than one year and are recorded at net realizable value. Accounts receivable are presented net of an allowance for credit losses resulting from the inability of customers to make required payments. The allowance for credit losses is based upon historical loss experience in combination with current economic conditions and a forecast of future economic conditions. Any change in the assumptions used in analyzing a specific account receivable might result in an additional allowance for credit losses being recognized in the period in which the change occurs. ICA historically has insignificant write-offs due to bad debts, and current conditions indicate all receivables are fully collectible. Therefore, no allowance for credit losses have been recognized at both September 30, 2024 and 2023.

Contributions and Grants Receivable

Contributions and grants receivable represent unconditional amounts committed to ICA. Contributions and grants receivable are reflected at either net realizable value, or at net present value based on projected cash flows. Contributions and grants receivable due in more than one year are discounted to present value based on management's estimate of the risk-adjusted rate of return. Management determines the allowance for doubtful accounts based upon review of outstanding receivables, historical collection information, and existing economic conditions. No allowance for uncollectible contributions and grants receivable has been established at both September 30, 2024 and 2023, as all amounts are deemed fully collectible.

Inventory

Inventory is comprised of brochures and is stated at the lower of cost or market value. Cost is determined on a first-in, first-out basis.

Revenue Recognition

Revenue Accounted for in Accordance with Contribution Accounting

ICA recognizes contributions and grants when cash, securities, or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give, that is, those with a measurable performance or other barrier, and a right of return, are not recognized until the conditions on which they depend have been met.

Interstitial Cystitis Association of America, Inc.

Notes to Financial Statements
September 30, 2024 and 2023

2. Summary of Significant Accounting Policies (continued)

Revenue Recognition (continued)

Revenue Accounted for in Accordance with Contribution Accounting (continued)

Cost-reimbursable grants are conditioned upon certain performance requirements and/or the incurrence of allowable qualifying expenses. Amounts received are recognized as revenue when ICA has incurred expenditures in compliance with specific grant provisions. Costs incurred in excess of cash received are reflected as grants receivable in the accompanying statements of financial position. Amounts received prior to incurring qualifying expenditures are reported as refundable advances in the accompanying statements of financial position.

Revenue Accounted for as Contracts with Customers

Revenue is recognized when ICA satisfies a performance obligation by transferring a promised good to, or performing a service for, a customer. The amount of revenue recognized reflects the consideration ICA expects to receive in exchange for satisfying distinct performance obligations. If a performance obligation does not meet the criteria to be considered distinct, ICA combines it with other performance obligations until a distinct bundle of goods or services exists. Fees or amounts received in advance of satisfying contractual performance obligations are reflected as deferred revenue in the statements of financial position. Revenue is recognized either over time or at the point in time that contractual obligations are met.

Specifically, for the various types of contracts, ICA recognizes revenue as follows:

ICA solicits organizations to become part of its corporate partnership program. Amounts received are considered exchange transactions and are recognized when earned.

Revenue from all other sources is recognized when earned.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the statements of activities. Accordingly, certain costs, such as management fees, have been allocated among the programs and supporting services, primarily based on employee effort.

Interstitial Cystitis Association of America, Inc.

Notes to Financial Statements
September 30, 2024 and 2023

2. Summary of Significant Accounting Policies (continued)

Advertising Costs

Advertising costs are expensed as incurred.

Subsequent Events

In preparing these financial statements, ICA has evaluated events and transactions for potential recognition, adjustment, or disclosure through March 12, 2025, the date the financial statements were available to be issued.

Subsequent to year end, ICA terminated its management services agreement. See Note 5.

3. Liquidity and Availability

ICA strives to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Management periodically reviews ICA's liquid asset needs and adjusts the cash balance as necessary.

Financial assets available for general expenditures, that is, without donor or other restrictions limiting their use, within one year of the statements of financial position date, comprise the following at September 30:

	2024	2023
Cash and cash equivalents	\$ 105,175	\$ 163,920
Accounts receivable	-	11,762
Contributions and grants receivable	26,500	137,860
Total available for general expenditures	<u>\$ 131,675</u>	<u>\$ 313,542</u>

4. Concentration of Credit Risk

Financial instruments that potentially subject ICA to significant concentrations of credit risk consist of cash and cash equivalents. ICA maintains various cash deposit and transaction accounts with financial institutions that, from time to time, could exceed insurable limits under the Federal Deposit Insurance Corporation (FDIC). ICA has not experienced any credit losses on its cash and cash equivalents to date as it relates to FDIC insurance limits. Management periodically assesses the financial condition of these financial institutions and believes that the risk of any credit loss is minimal.

Interstitial Cystitis Association of America, Inc.

Notes to Financial Statements September 30, 2024 and 2023

5. Commitments and Contingencies

Management Services

ICA utilized the services of a management services company, MCI USA (MCI) under the terms of a written agreement. The agreement, as amended, provided for a core management fee of \$30,948 per month and was subject to annual fee escalations. The fee increases were pursuant to the annual escalation rate specified in the contract. In addition, MCI was entitled to reimbursement for any direct costs incurred on behalf of ICA not covered under the scope of the management agreement. Core management fees totaled \$433,968 and \$421,331 for the years ended September 30, 2024 and 2023, respectively.

Pursuant to the agreement, subsequent to year end, on December 6, 2024, ICA terminated its management services agreement with MCI.

Government Grants

Funds received from federal agencies (including pass-throughs) are subject to an audit under the provisions of the grant agreements. The ultimate determination of amounts received under these grants is based upon the allowance of costs reported to and accepted by the oversight agencies. Until such grants are closed out, a potential contingency exists to refund any amounts received in excess of allowable costs. Management is of the opinion that no material liability exists.

6. Income Taxes

ICA is recognized as a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code, and is exempt from income taxes except for taxes on unrelated business activities. No tax expense is recorded in the accompanying financial statements for the years ended September 30, 2024 and 2023, as there were no unrelated business activities.

Management has evaluated ICA's tax positions and has concluded that ICA has taken no uncertain tax positions that qualify for either recognition or disclosure in the accompanying financial statements.